Our pipeline is driven by our revolutionary research into immune response. Each product builds on our unique understanding of innate immunity and how this natural control can be used to destroy solid tumors, provide functional cures for chronic viral infection, and prevent disease.

ASD141 – Innate ICI for immuno-oncology

ASD141 is a novel, innate immune checkpoint inhibitor (ICI) that commands the innate immune system to coordinate a renewed attack on solid tumors. As a monotherapy, ASD141 shows statistically significant inhibition of tumor growth in animal cancer models. When used in combination therapy with adaptive-immunity-targeted anti-PD1 and anti-CTLA4 ICIs, ASD141 further decreased tumor growth and increased survival rates (in animal studies).

We have received FDA clearance on first-in-human clinical trail.

ASD253 – Therapeutic vaccine for chronic HBV infection

Developed using NanoCherub®, ASD253 is a therapeutic vaccine developed against chronic hepatitis B virus (HBV) infection. Animal models have shown good safety profiles and 100% HBV S-antigen seroconversion in both hydrodynamic injection and AAV transduced HBV models.

ASD001 – Discovery studies on autoimmune diseases and neurodegeneration diseases

Interested in being part of our journey?

We are interested in hearing from partners who are interested in co-developing or licensing ASD141 or investors who are interested in being part of this journey.

Contact our team for more information:

Get in touch